Ocugen reports FY2022 net loss per share $0.38; cash runway into Q1 2024; OCU400 enrollment complete

Ocugen, Inc.

2022-FY EPS reported -$0.38 revenue$2,488,000

FY2022 net loss $0.38/share vs $0.30 prior year; Q4 net loss $0.10/share vs $0.07.
Cash, equivalents, and investments $90.9M as of Dec 31, 2022; estimated runway into Q1 2024.
OCU400 Phase 1/2 RP enrollment completed; high dose set; Phase 3 targeted end of 2023.
IND submitted for OCU200 (diabetic macular edema); OCU410/OCU410ST IND planned Q2 2023.
NeoCart Phase 3 trial design agreed with FDA; start expected H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ocugen, Inc. reported the year ended December 31, 2022 results: EPS $0.38 net loss per common share.

Period: the year ended December 31, 2022
EPS: $0.38 net loss per common share
Result: reported results

Exact text from the filing

Ocugen reported a $0.38 net loss per common share for the year ended December 31, 2022, compared to a $0.30 net loss per common share for the year ended December 31, 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ocugen, Inc. reported the three months ended December 31, 2022 results: EPS $0.10 net loss per common share.

Period: the three months ended December 31, 2022
EPS: $0.10 net loss per common share
Result: reported results

Exact text from the filing

Ocugen reported a $0.10 net loss per common share for the three months ended December 31, 2022, compared to a $0.07 net loss per common share for the three months ended December 31, 2021.

View on SEC.gov

Browse all earnings releases →

Ocugen, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-005369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.